Analyst Price Targets — GMAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 22, 2026 10:15 am | — | New Street | $43.00 | $28.37 | StreetInsider | TD Cowen Upgrades Genmab A/S (GMAB) to Buy |
| May 27, 2026 10:09 am | Gregory Renza | Truist Financial | $40.00 | $26.89 | StreetInsider | Truist Securities Assumes Genmab A/S (GMAB) at Buy |
| April 30, 2026 10:12 am | — | H.C. Wainwright | $38.00 | $26.11 | TheFly | Genmab price target lowered to $38 from $40 at H.C. Wainwright |
| March 26, 2026 8:11 pm | — | Wolfe Research | $32.00 | $26.03 | TheFly | Genmab initiated with an Outperform at Wolfe Research |
| February 23, 2026 11:31 am | Michael Schmidt | Guggenheim | $40.00 | $29.29 | TheFly | Genmab price target lowered to $40 from $45 at Guggenheim |
| February 17, 2026 9:26 am | Benjamin Jackson | Jefferies | $41.50 | $30.03 | TheFly | Genmab resumed with a Buy at Jefferies |
| January 20, 2026 11:18 am | — | H.C. Wainwright | $39.00 | $32.25 | TheFly | Genmab price target lowered to $39 from $41 at H.C. Wainwright |
| November 6, 2025 8:03 pm | Asthika Goonewardene | Truist Financial | $48.00 | $28.84 | StreetInsider | Genmab A/S (GMAB) PT Lowered to $48 at Truist Securities |
| October 6, 2025 11:12 am | Asthika Goonewardene | Truist Financial | $49.00 | $33.56 | TheFly | Genmab price target raised to $49 from $46 at Truist |
| October 2, 2025 12:52 pm | — | H.C. Wainwright | $40.00 | $31.77 | TheFly | Genmab price target raised to $40 from $36 at H.C. Wainwright |
Latest News for GMAB
Genmab A/S Sponsored ADR (NASDAQ: GMAB - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $35.66 and last traded at $35.3850, with a volume of 234834 shares. The stock had previously closed at $35.22. Wall Street Analysts Forecast Growth GMAB has been the subject of
Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Genmab A/S (GMAB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for GMAB.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.